S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

$40.57
-1.18 (-2.83%)
(As of 02/28/2024 ET)
Today's Range
$40.30
$41.60
50-Day Range
$40.00
$70.16
52-Week Range
$38.22
$114.65
Volume
354,577 shs
Average Volume
351,094 shs
Market Capitalization
$442.21 million
P/E Ratio
4.45
Dividend Yield
N/A
Price Target
$61.00

Medifast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
50.4% Upside
$61.00 Price Target
Short Interest
Bearish
17.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-4.17
Upright™ Environmental Score
News Sentiment
0.26mentions of Medifast in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.65%
From $4.92 to $5.69 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Consumer Staples Sector

43rd out of 138 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 4 stocks


MED stock logo

About Medifast Stock (NYSE:MED)

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is based in Baltimore, Maryland.

MED Stock Price History

MED Stock News Headlines

Don't Get Near These 10%+ Dividend Yield Stocks
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Medifast Full Year 2023 Earnings: EPS Misses Expectations
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Medifast Shares Drop 16% After Lower 4Q Earnings
Q4 2023 Medifast Inc Earnings Call
Medifast, Inc. (NYSE:MED) Q4 2023 Earnings Call Transcript
Recap: Medifast Q4 Earnings
Medifast: Q4 Earnings Snapshot
Medifast Q4 2023 Earnings Preview
Medifast earnings: here's what Wall Street expects
A Preview Of Medifast's Earnings
MED Mar 2024 55.000 call
Medifast (MED) Reports Earnings Tomorrow. What To Expect
GPS Feb 2024 15.500 put
See More Headlines
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
2/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
874
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.00
High Stock Price Target
$82.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+50.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$99.42 million
Pretax Margin
12.01%

Debt

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$10.85 per share
Book Value
$18.49 per share

Miscellaneous

Free Float
10,672,000
Market Cap
$442.21 million
Optionable
Optionable
Beta
1.22
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Daniel R. ChardMr. Daniel R. Chard (Age 59)
    Executive Chairman & CEO
    Comp: $1.94M
  • Mr. James P. Maloney CPA (Age 56)
    Chief Financial Officer
    Comp: $823.91k
  • Mr. Anthony E. Tyree (Age 59)
    Chief Business Operations Officer
    Comp: $655.86k
  • Mr. Jason L. Groves Esq. (Age 53)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $669.51k
  • Mr. Nicholas M. Johnson (Age 44)
    Chief Field Operations Officer
    Comp: $696.4k
  • Mr. Jonathan Barrett MacKenzie (Age 52)
    VP of Finance & Chief Accounting Officer
  • Mr. Steven Zenker
    Vice President of Investor Relations
  • Ms. Claudia C. Greninger (Age 51)
    Chief Human Resources Officer














MED Stock Analysis - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for Medifast's stock. Their MED share price targets range from $40.00 to $82.00. On average, they predict the company's share price to reach $61.00 in the next year. This suggests a possible upside of 50.4% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2024?

Medifast's stock was trading at $67.22 at the beginning of the year. Since then, MED shares have decreased by 39.6% and is now trading at $40.57.
View the best growth stocks for 2024 here
.

Are investors shorting Medifast?

Medifast saw a increase in short interest in January. As of January 31st, there was short interest totaling 1,920,000 shares, an increase of 7.3% from the January 15th total of 1,790,000 shares. Based on an average trading volume of 258,600 shares, the days-to-cover ratio is currently 7.4 days. Currently, 18.0% of the shares of the stock are short sold.
View Medifast's Short Interest
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) announced its quarterly earnings data on Tuesday, February, 20th. The specialty retailer reported $1.09 EPS for the quarter, topping the consensus estimate of $0.99 by $0.10. The specialty retailer had revenue of $191.02 million for the quarter, compared to analyst estimates of $184.17 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 56.06%. Medifast's quarterly revenue was down 43.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.70 EPS.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, September 7th. Stockholders of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a dividend yield of 16.27%. The ex-dividend date of this dividend is Monday, September 18th.
Read our dividend analysis for MED
.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 0.250-0.950 for the period, compared to the consensus earnings per share estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Who are Medifast's major shareholders?

Medifast's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (15.49%), Pacer Advisors Inc. (4.80%), First Trust Advisors LP (3.65%), Dimensional Fund Advisors LP (2.85%), Charles Schwab Investment Management Inc. (1.71%) and Hotchkis & Wiley Capital Management LLC (1.54%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:MED) was last updated on 2/29/2024 by MarketBeat.com Staff